Experimental and Therapeutic Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2022-06-29 骞骞F文章

审稿速度:1.0 | 投稿命中率:75.0
经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的

63 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2022-11-14 ms3000000235546431

感谢分享

29 0

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2020-09-23 ms8000000548825590

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：颗粒物;毒理
经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？

139 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2022-10-18 ms5000001622730751

偏重的研究方向：药理;中药复方
经验分享：请问收网络药理加实验吗

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2020-09-07 ms5000000364586422

审稿速度:12.0 | 投稿命中率:50.0
经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了

101 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2022-05-11 ms6000001101669014

去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。
请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？

53 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2022-08-29 ms5000001731462752

审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗

37 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2022-08-11 乐心肠

2022不是预警期刊了么

47 0

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2022-07-21 ms7000001267392139

请问投过的战友这个杂志要求查重率低于多少？

43 0

[GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：4月28投稿，6月22接受。十分顺利，没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向：药理;中药复方 经验分享：请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Reprints交费页面，大家怎么处理的？不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊，今年2月末给修回并让转投ETM这本，4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回，4月末交了版面费，5月官网显示published，但PubMed上还没能搜到。 请问一下大家大概在published到PubMed能搜到大概需要多长时间呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊，2个月了一点消息没有，这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友这个杂志要求查重率低于多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232566, encodeId=73421232566a1, content=今年影响因子是多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98398160268, createdName=ms8000000572095839, createdTime=Fri Jul 15 07:12:02 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

2022-07-15 ms8000000572095839

今年影响因子是多少

45 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务